-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] With the continuous improvement of the innovation strength of local pharmaceutical companies, China's contribution to global pharmaceutical innovation is also increasi.
Driven by multiple favorable policies, capital, talents, e.
, the pace of domestic innovative drugs listing continues to accelera.
The process of internationalization is also accelerati.
On May 18, according to Endpoint news, Hengrui Medicine established a wholly-owned subsidiary, Luzsana Biotechnology, responsible for the internationalization (overseas development and commercialization) of Hengrui Medicine's pipeline produc.
It is understood that Hengrui will put a portion of its assets into Luzsana, which will be responsible for drug development and commercialization in markets outside of China, currently involving more than 250 clinical studies, covering oncology, cardiovascular, metabolism/diabetes, pain management, Immunology, liver and kidney disease and other clinical needs are m.
In recent years, Hengrui Medicine has been accelerating the pace of international developme.
In addition to the establishment of new companies, according to incomplete statistics, Hengrui Medicine has carried out a total of nearly 20 international clinical trials, including 7 international multi-center Phase III projects, and More than 10 studies are in the preparatory sta.
At present, some powerful local innovative pharmaceutical companies are accelerating the pace of product internationalizati.
In addition to Hengrui Medicine, BeiGene is also one of the companies with more international layouts and faster progre.
It is reported that on February 19 this year, BeiGene announced that its zanubrutinib has been approved by the Swiss Food and Drug Administration for the treatment of Waldenström macroglobulinemia (WM) adults who have received at least one prior thera.
Or as a first-line treatment option for WM patients who are not suitable for chemoimmunothera.
The product has been approved for the first time in the world in the United States in November 2019, and has become a new domestic anti-cancer drug for overseas u.
It has subsequently been approved for listing in China, Canada, Australia, Russia, the European Union and other countries and regio.
At present, its commercial The chemical footprint has spread to 44 markets around the wor.
In addition, there are still more than 40 drug regulatory filings under review worldwi.
In addition, Huiyu Pharmaceutical has also stated that the company will further advance and refine its work in the international market by relying on its established international sales channels and tea.
The company will improve the management system of partners according to the conditions of different countries and regions, strengthen market information collection and analysis capabilities, establish a company-specific database of global markets and partners, track the development and changes of global pharmaceuticals, and fully analyze the market environment in key regio.
Operation model, intensive cultivation, and become an international pharmaceutical compa.
It should be noted that under the general trend of pharmaceutical companies accelerating their "going overseas", the internationalization of pharmaceutical companies is actually not smooth saili.
On May 6, Innovent and Coherus jointly announced the termination of the collaboration on bevacizumab biosimilar IBI-30Innovent said that this business decision was made after evaluating the North American market dynamics of bevacizumab biosimilars and delays in development due to the ongoing impact of the epidem.
Recently, Junshi Bio's tumor immunotherapy drug PD-1 for the treatment of nasopharyngeal carcinoma in the United States was rejected by the F.
Previously, the listing process of Chi-Med's surufatinib in the United States was also pressed on the pause button; in addition, Innovent and Coherus also jointly announced the termination of the cooperation on the bevacizumab biosimilar IBI-30
From the current Judging from the situation of companies going overseas, domestic biopharmaceutical companies are not going smoothly, and there is still a long way to go for the international development of domestic dru.
In this regard, the industry believes that the globalization strategy of innovative pharmaceutical companies should focus on good product pipelines, that is, good products must be developed first, and only good products can be brought to the world; secondly, drug development must be based on the earliest The principle of intervening in internationalization is the principle, rather than considering internationalization when thinking about listing; in addition, in the early stage of the layout, a corresponding clinical operation team should be established overseas, a professional talent research team should be built locally, and it should be able to communicate directly with the F.
In general, the industry still generally believes that the global development of Chinese innovative drugs is the only w.
But at the same time, understanding the international market conditions, making up for their own shortcomings, and seeking strong external partners will be an important strategy for the development of innovative drug compani.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Driven by multiple favorable policies, capital, talents, e.
, the pace of domestic innovative drugs listing continues to accelera.
The process of internationalization is also accelerati.
On May 18, according to Endpoint news, Hengrui Medicine established a wholly-owned subsidiary, Luzsana Biotechnology, responsible for the internationalization (overseas development and commercialization) of Hengrui Medicine's pipeline produc.
It is understood that Hengrui will put a portion of its assets into Luzsana, which will be responsible for drug development and commercialization in markets outside of China, currently involving more than 250 clinical studies, covering oncology, cardiovascular, metabolism/diabetes, pain management, Immunology, liver and kidney disease and other clinical needs are m.
In recent years, Hengrui Medicine has been accelerating the pace of international developme.
In addition to the establishment of new companies, according to incomplete statistics, Hengrui Medicine has carried out a total of nearly 20 international clinical trials, including 7 international multi-center Phase III projects, and More than 10 studies are in the preparatory sta.
At present, some powerful local innovative pharmaceutical companies are accelerating the pace of product internationalizati.
In addition to Hengrui Medicine, BeiGene is also one of the companies with more international layouts and faster progre.
It is reported that on February 19 this year, BeiGene announced that its zanubrutinib has been approved by the Swiss Food and Drug Administration for the treatment of Waldenström macroglobulinemia (WM) adults who have received at least one prior thera.
Or as a first-line treatment option for WM patients who are not suitable for chemoimmunothera.
The product has been approved for the first time in the world in the United States in November 2019, and has become a new domestic anti-cancer drug for overseas u.
It has subsequently been approved for listing in China, Canada, Australia, Russia, the European Union and other countries and regio.
At present, its commercial The chemical footprint has spread to 44 markets around the wor.
In addition, there are still more than 40 drug regulatory filings under review worldwi.
In addition, Huiyu Pharmaceutical has also stated that the company will further advance and refine its work in the international market by relying on its established international sales channels and tea.
The company will improve the management system of partners according to the conditions of different countries and regions, strengthen market information collection and analysis capabilities, establish a company-specific database of global markets and partners, track the development and changes of global pharmaceuticals, and fully analyze the market environment in key regio.
Operation model, intensive cultivation, and become an international pharmaceutical compa.
It should be noted that under the general trend of pharmaceutical companies accelerating their "going overseas", the internationalization of pharmaceutical companies is actually not smooth saili.
On May 6, Innovent and Coherus jointly announced the termination of the collaboration on bevacizumab biosimilar IBI-30Innovent said that this business decision was made after evaluating the North American market dynamics of bevacizumab biosimilars and delays in development due to the ongoing impact of the epidem.
Recently, Junshi Bio's tumor immunotherapy drug PD-1 for the treatment of nasopharyngeal carcinoma in the United States was rejected by the F.
Previously, the listing process of Chi-Med's surufatinib in the United States was also pressed on the pause button; in addition, Innovent and Coherus also jointly announced the termination of the cooperation on the bevacizumab biosimilar IBI-30
From the current Judging from the situation of companies going overseas, domestic biopharmaceutical companies are not going smoothly, and there is still a long way to go for the international development of domestic dru.
In this regard, the industry believes that the globalization strategy of innovative pharmaceutical companies should focus on good product pipelines, that is, good products must be developed first, and only good products can be brought to the world; secondly, drug development must be based on the earliest The principle of intervening in internationalization is the principle, rather than considering internationalization when thinking about listing; in addition, in the early stage of the layout, a corresponding clinical operation team should be established overseas, a professional talent research team should be built locally, and it should be able to communicate directly with the F.
In general, the industry still generally believes that the global development of Chinese innovative drugs is the only w.
But at the same time, understanding the international market conditions, making up for their own shortcomings, and seeking strong external partners will be an important strategy for the development of innovative drug compani.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
